Cargando…
Does Dry Eye Disease Severity Impact Efficacy of Varenicline Solution Nasal Spray on Sign and Symptom Treatment Outcomes?
There is a clinical necessity for dry eye disease treatments that perform across a broad range of presenting patient severities. Varenicline solution nasal spray (VNS), a unique cholinergic agonist ocular surface–sparing nasal spray therapy, demonstrated significant improvement in both signs and sym...
Autores principales: | Sheppard, John D., O'Dell, Leslie E., Karpecki, Paul M., Raizman, Michael B., Whitley, Walter O., Blemker, Gretchen, Hemphill, Mandy, Hendrix, Laura H., Gibson, Andrea, Macsai, Marian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970014/ https://www.ncbi.nlm.nih.gov/pubmed/36728653 http://dx.doi.org/10.1097/OPX.0000000000001986 |
Ejemplares similares
-
OC-01 (Varenicline Solution) Nasal Spray for the Treatment of Dry Eye Disease Signs and Symptoms in Subjects with Autoimmune Disease: Integrated Data from ONSET-1 and ONSET-2
por: Schallhorn, Julie M, et al.
Publicado: (2023) -
OC-01 (Varenicline Solution) Nasal Spray Demonstrates Consistency of Effect Regardless of Age, Race, Ethnicity, and Artificial Tear Use
por: Epitropoulos, Alice T, et al.
Publicado: (2022) -
Does Menopausal Status Affect Dry Eye Disease Treatment Outcomes with OC-01 (Varenicline Solution) Nasal Spray? A Post Hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials
por: Nijm, Lisa M., et al.
Publicado: (2022) -
Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease
por: Hauswirth, Scott G, et al.
Publicado: (2023) -
Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease
por: White, Darrell E, et al.
Publicado: (2023)